With this collaboration, CardioSignal’s motion sensor technology for heart disease detection is made available for healthcare professionals by combining it with Roche’s blood glucometer.

With a large population with over half a billion smartphone users and growing demand for at-home solutions in heart health monitoring, India is the next natural step in CardioSignal’s global expansion.

As the Chief Medical Officer and General Manager of US operations, Dr. Alastalo brings CardioSignal expertise, access and a strong track record to establishing operations in the United States.

CardioSignal is developing a disruptive mobile application-based technology to improve the detection of heart disease. Utilizing sensitive motion sensors in modern smartphones, the CardioSignal application detects heart motion with high accuracy.

Precordior leads integration of the advanced bed monitoring system developed in the Moore4Medical project in 2020–2023 for detection of atrial fibrillation during sleep. Heart failure monitoring and detection of coronary artery disease are also studied in the project.

EU funding will accelerate the development and global market entry preparation of the CardioSignal by Precordior® product family to include detection of Heart Failure and Coronary Artery Disease with built-in smartphone motion sensors, the new revolutionary smartphone-only technology.